Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,800 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
Aggarwal A, Akerman A, Milogiannakis V, Silva MR, Walker G, Stella AO, Kindinger A, Angelovich T, Waring E, Amatayakul-Chantler S, Roth N, Manni S, Hauser T, Barnes T, Condylios A, Yeang M, Wong M, Jean T, Foster CSP, Christ D, Hoppe AC, Munier ML, Darley D, Churchill M, Stark DJ, Matthews G, Rawlinson WD, Kelleher AD, Turville SG. Aggarwal A, et al. Among authors: wong m. EBioMedicine. 2022 Oct;84:104270. doi: 10.1016/j.ebiom.2022.104270. Epub 2022 Sep 18. EBioMedicine. 2022. PMID: 36130476 Free PMC article.
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
Akerman A, Milogiannakis V, Jean T, Esneau C, Silva MR, Ison T, Fichter C, Lopez JA, Chandra D, Naing Z, Caguicla J, Li D, Walker G, Amatayakul-Chantler S, Roth N, Manni S, Hauser T, Barnes T, Condylios A, Yeang M, Wong M, Foster CSP, Sato K, Lee S, Song Y, Mao L, Sigmund A, Phu A, Vande More AM, Hunt S, Douglas M, Caterson I, Britton W, Sandgren K, Bull R, Lloyd A, Triccas J, Tangye S, Bartlett NW, Darley D, Matthews G, Stark DJ, Petoumenos K, Rawlinson WD, Murrell B, Brilot F, Cunningham AL, Kelleher AD, Aggarwal A, Turville SG. Akerman A, et al. Among authors: wong m. EBioMedicine. 2023 Apr;90:104545. doi: 10.1016/j.ebiom.2023.104545. Epub 2023 Mar 30. EBioMedicine. 2023. PMID: 37002990 Free PMC article.
First detection of SARS-CoV-2 variant B.1.1.529 (Omicron) in Ecuador.
Carrazco-Montalvo A, Armendáriz-Castillo I, Tello CL, Morales D, Armas-Gonzalez R, Guizado-Herrera D, León-Sosa A, Ramos-Sarmiento D, Fuertes B; USFQ-Consortium; Patino L. Carrazco-Montalvo A, et al. New Microbes New Infect. 2022 Jan;45:100951. doi: 10.1016/j.nmni.2022.100951. Epub 2022 Jan 7. New Microbes New Infect. 2022. PMID: 35018222 Free PMC article.
Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.
Dasgupta I, Meadowcroft AM, Bhatt PR, Acharya A, Aarup M, Correa-Rotter R, Gupta S, Kher VK, Neto OMV, Rastogi A, Ots-Rosenberg M, Rayner B, Wong MG, Shah S, Taft L, Singh AK. Dasgupta I, et al. Among authors: wong mg. Nephrol Dial Transplant. 2024 Nov 21:gfae273. doi: 10.1093/ndt/gfae273. Online ahead of print. Nephrol Dial Transplant. 2024. PMID: 39817409
Cohort profile: the potentially preventable burden of community-acquired pneumonia in South African adults in the era of widespread PCV13 immunisation and antiretroviral therapy roll-out, before and during the COVID-19 pandemic - the multicentre, multimethod PotPrev Study.
Nabeemeeah F, Sabet N, Otwombe K, Hlongwane K, Mlambo LM, Moloantoa T, Wong M, Mangena P, Abraham P, Swanepoel F, Moosa F, von Gottberg A, Cohen C, Southern J, Fletcher M, Dunne E, Ndungane-Tlakula B, Begier E, Gray S, Gessner BD, Naidoo J, Milovanovic M, Variava E, Martinson N. Nabeemeeah F, et al. Among authors: wong m. BMJ Open. 2024 Dec 20;14(12):e080553. doi: 10.1136/bmjopen-2023-080553. BMJ Open. 2024. PMID: 39806691 Free PMC article.
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer.
Chen Z, Chen J, Huang D, Zhang W, Wu L, Yi T, Wang Q, Han L, Tan L, Li Y, Zhang Z, Li N, Li J, Zhang T, Hu Y, Sun H, Wu Y, He Z, Yang R, Cheng P, Li X, Shi J, Yu G, Ma D, Li BX, Dai X, Wong M, Li Y, Yu X, Lu S; Socazolimab Study Group. Chen Z, et al. Among authors: wong m. Signal Transduct Target Ther. 2025 Jan 13;10(1):28. doi: 10.1038/s41392-024-02115-5. Signal Transduct Target Ther. 2025. PMID: 39800716 Free PMC article. Clinical Trial.
8,800 results